Sagimet Biosciences To Host Conference Call And Webcast On June 13, 2024, To Discuss Positive Data From FASCINATE-2 Phase 2b Trial Of Denifanstat In MASH Patients Presented At EASL Congress
Portfolio Pulse from Benzinga Newsdesk
Sagimet Biosciences will host a conference call and webcast on June 13, 2024, to discuss positive data from the FASCINATE-2 Phase 2b trial of Denifanstat in MASH patients, presented at the EASL Congress.
June 10, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sagimet Biosciences will discuss positive Phase 2b trial data for Denifanstat in MASH patients, which could boost investor confidence and stock price.
The positive data from the Phase 2b trial of Denifanstat in MASH patients is a significant milestone for Sagimet Biosciences. The upcoming conference call and webcast to discuss these results could increase investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100